San Diego, CA (PRWEB) June 07, 2013
In its latest consumer update involving federal court lawsuits with allegations* that the use of the popular blood thinner Pradaxa may cause internal bleeding problems Resource4thePeople is reporting that an important court hearing has been scheduled.
The federal judge in the Southern District of Illinois overseeing these consolidated cases involving Pradaxa lawsuits filed across the country has scheduled a June 10, 2013 status conference in the case, according to the court docket.*
The court file also shows that the number of cases that have been included in this federal multidistrict litigation has climbed to 954. The cases have been consolidated because they make the same claims, as outlined in the court file:
“All the actions share common factual questions arising out of allegations that plaintiffs suffered severe bleeding or other injuries as a result of taking the drug Pradaxa (dabigatran etexilate) and that defendants did not adequately warn prescribing physicians of the risks associated with Pradaxa, including the potential for severe or fatal bleeding, and that there is no reversal agent to counteract the Pradaxa’s anticoagulation effects. Centralization will eliminate duplicative discovery; prevent inconsistent pretrial rulings; and conserve the resources of the parties, their counsel and the judiciary.”
“These status hearings are important milestones in multidistrict litigations such as the Pradaxa one before U.S. District Court Judge David R. Herndon because it brings together the legal teams for the plaintiffs and Pradaxa in a court hearing open to the public,” said Resource4thePeople.
“The judge is briefed on the progress of the litigation, including legal problems that have surfaced. For consumers who are affected or interested in these Pradaxa lawsuits important information often surfaces because these are public hearings.”
Resource4thePeople also notes that the number of Pradaxa lawsuits alleging internal bleeding problems is now nearing 1,000 and the number of consumer inquiries about legal options available to them has been increasing.
Of particular interest to consumers, according to the input Resource4thePeople has been receiving is that the fact that Judge Herndon has scheduled a series of bellwether, or test trials that will begin later this year.
"In response to questions we have been receiving from consumers, the fact that trials have been scheduled does not prevent anyone who has suffered alleged bleeding incidents from the use of Pradaxa to file their own lawsuit while this litigation moves forward."
Resource4thePeople's national network of lawyers will continue to be available for free consultations in which consumers can be informed about their eligibility to seek compensation over alleged internal bleeding problems involving the use of Pradaxa.
According to the court docket in this multidistrict litigation, Judge Herndon has scheduled the first set of bellwether trials for August 11, 2014, November 3, 2014, January 5, 2015 and February 16, 2015 and designated these as "Early Trial Cases."
The plaintiffs are seeking compensation for the medical costs and other expenses they allege they have incurred as a result of using Pradaxa to protect against strokes and heart attacks, according to the court file.
Resource4thePeople also will continue to update consumers about the important developments in the Pradaxa multidistrict litigation.
In scheduling the bellwether trials, Judge Herndon also outlined the allegations that will be included in the selection of the individual cases. Among the criteria he listed on the court docket in his April 9, 2013 order are:
Pradaxa’s manufacturer, Boehringer Ingelheim, has denied the claims that have been filed against them in the litigation, including allegations contained in the complaints that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects, according to the court file.*
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred, according to the court filings.
Bloomberg News, in a Dec. 11, 2012 posting, reported** that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”
Bloomberg also reported** that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011."
Resource4thePeople also is advising consumers who may have been or are being treated with Pradaxa that the FDA recently issued a Drug Safety Communication warning that the medication should not be used in patients with mechanical prosthetic heart valves.***
Read the full story at http://www.prweb.com/releases/2013/6/prweb10801871.htm.
Copyright©2012 Vocus, Inc.
All rights reserved